NCT05745337View on ClinicalTrials.gov

Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Atrial FibrillationDiastolic DysfunctionHFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)

Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor

Trial Locations (1)

05405

RECRUITING

University of Vermont Medical Center, Burlington

All Listed Sponsors
lead

University of Vermont

OTHER